Plasmid Name
pHCIgG1V308P
Mutation Set
V308P (CH2 domain)
Selection Marker
Ampicillin
Promoter
CMV
Fc Engineering Overview
The Human IgG1 (V308P) — V308P Fc Variant introduces a single point substitution (Val308 to Pro) in the CH2 domain designed to modulate FcRn dissociation kinetics. This enables controlled and accelerated systemic clearance (~2–5-day half-life) without completely abrogating FcRn engagement, offering an intermediate clearance window between wild-type IgG1 (~21 days) and complete FcRn knockout variants like I253A.
Functional Profile
| Property | Effect |
|---|---|
| FcγR binding | Maintained / WT Baseline |
| ADCC | Maintained / WT Baseline |
| CDC | Maintained / WT Baseline |
| FcRn binding | Altered / Reduced ↓ |
| Serum half-life | Shortened / Accelerated clearance ↓ |
| PK profile | Controlled fast-clearance (~ 2-5 days) |
Mechanism of Action
The V308P Fc variant introduces a single point substitution—Val308 to Pro—within the loop region of the CH2 domain at the FcRn binding interface. The rigid proline substitution alters local backbone conformation and perturbs optimal hydrogen bonding and hydrophobic contact with FcRn. This speeds up endosomal dissociation and reduces intracellular recycling efficiency, resulting in accelerated clearance while avoiding the immediate, complete ablation seen with total FcRn knockout variants like I253A.
Phenotypic Effects
- Moderately reduced FcRn binding affinity at endosomal acidic pH (pH 6.0).
- Accelerated systemic clearance rate (2 -5-day serum half-life in human/primate models).
- Provides intermediate clearance rate between wild-type IgG1 (~ 21 days) and FcRn-null variants (hours).
- Retains wild-type effector functions (ADCC, ADCP, and CDC).
- Preserves overall conformational stability and expression yields.
Applications
- Antibody-drug conjugates (ADCs) designed to minimize systemic toxicity from long circulation.
- Immuno-PET imaging and diagnostic radioimmunotherapy requiring clear background contrast within days.
- Bispecific or toxic biologics requiring rapid off-target clearance windows.
- Mechanistic control for calibrating FcRn recycling threshold models.
Sequence Map & Feature Annotation
Insert Architecture: VH - CH1 - hinge - CH2(V308P) - CH3
- VH: Variable heavy domain
- CH1: Constant heavy 1
- Hinge: Native IgG1 hinge
- CH2(V308P): FcRn-modulating fast-clearance mutation
- CH3: Constant heavy 3
Product Note: The V308P Fc variant is an essential tool for applications where long serum persistence is undesirable or toxic. It provides a finely tuned “middle ground” for accelerated clearance, ensuring that circulating therapeutic or diagnostic constructs clear within several days rather than several weeks or a few hours.
Comparison within Fusion BioLabs FcRn / PK-Modulated Fc Variant Family
| Variant | Mechanism | Strength (PK Extension) | Primary Application & Notes |
|---|---|---|---|
| human IgG1 (WT) (Wild-Type) |
Native FcRn binding | ★★☆☆☆ | Baseline Control. Standard physiological baseline (∼21-day half-life in humans). |
| human IgG1 (N434A) N434A |
Single-point FcRn-enhanced | ★★★☆☆ | Single-point mutation providing a moderate 1.5–2× PK boost with low immunogenicity risk and easy manufacturing integration. |
| human IgG1 (LA) M428L / N434A |
FcRn-enhanced | ★★★★☆ | Strong PK Extension. Dual mutation combining M428L and N434A; enhances acidic FcRn binding with minimal neutral binding. |
| human IgG1 (LS) M428L / N434S |
FcRn-enhanced | ★★★★★ | Very Strong PK Extension. Extends human serum half-life up to 3–5× (>70–90 days; e.g., tixagevimab/ cilgavimab). |
| human IgG1 (YTE) M252Y / S254T / T256E |
FcRn-enhanced | ★★★★★ | Benchmark PK Extension. Industry-standard benchmark delivering ∼3–4× PK boost in humans (e.g., nirsevimab / Beyfortus®). |
| human IgG1 (QL) T250Q / M428L |
FcRn-enhanced | ★★★★☆ | Moderate-to-Strong PK Extension. Increases acidic FcRn affinity with favorable intellectual property freedom to operate. |
| human IgG1 (YTE + KF) M252Y/S254T/T256E + H433K/N434F |
Hyper-FcRn-enhanced / FcRn Blocker | ★★★★★ | FcRn Antagonist / Autoimmune Control. Binds tightly across pH 6.0 and 7.4 to block FcRn recycling and clear endogenous IgGs. |
| human IgG1 (V308P) V308P |
Controlled/Accelerated Clearance | ★★☆☆☆ | This Product. Tunable Fast-Clearance Variant. Modulates FcRn dissociation kinetics to yield accelerated clearance (2–5-day half-life); ideal for ADCs and immuno-PET imaging to limit non-target toxicity. |
| human IgG1 (I253A) I253A |
FcRn-null / Abrogated | ★☆☆☆☆ | Ultra-Fast Clearance Control. Complete knockout of the core FcRn binding triad; rapidly cleared within hours. |
Storage & Handling
- Store plasmid at –20°C.
- Avoid repeated freeze–thaw cycles.
- Use sterile technique when handling.
- Suitable for transient or stable mammalian expression.
References
- Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591-6604.
- Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos. 2007;35(1):86-94.
